Great episode Dr Ross Camidge's podcast #HowThisIsBuildingMe with pharmacologist Dr. Zirkelbach (FDA Onc) on drug dev & her focus on #PROs for best outcomes w/fewest AEs
I always learn, but still have questions about #ProjectOptimus
bit.ly/48RlOpz
#LCAM #LCSM #TheRightDose
@itsnotpink.bsky.social
I always learn, but still have questions about #ProjectOptimus
bit.ly/48RlOpz
#LCAM #LCSM #TheRightDose
@itsnotpink.bsky.social
FDA Involvement in Dose Optimization Through Project Optimus Drives a Patient-Focused Oncology Pharmacology Career: With D. Ross Camidge, MD, PhD; and Jeanne Fourie Zirkelbach, PhD
Drs Camidge and Zirkelbach discuss Zirkelbach's first pharmacokinetics forays and her involvement with reforming dose optimization in drug development.
bit.ly
November 14, 2024 at 1:38 PM
Great episode Dr Ross Camidge's podcast #HowThisIsBuildingMe with pharmacologist Dr. Zirkelbach (FDA Onc) on drug dev & her focus on #PROs for best outcomes w/fewest AEs
I always learn, but still have questions about #ProjectOptimus
bit.ly/48RlOpz
#LCAM #LCSM #TheRightDose
@itsnotpink.bsky.social
I always learn, but still have questions about #ProjectOptimus
bit.ly/48RlOpz
#LCAM #LCSM #TheRightDose
@itsnotpink.bsky.social
Great workshop and talk #YingYuan
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25
April 25, 2025 at 9:08 PM
Great workshop and talk #YingYuan
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25